Asthma

The cost and adverse events associated with corticosteroids need to be considered for patients with severe asthma.

Instructional methods can improve effectiveness of hand-held inhalers for asthma and chronic obstructive pulmonary disease.

Population growth and aging cause increase in disease burden from asthma and chronic obstructive pulmonary disease.

The prevalence of lung conditions worldwide has increased, despite the overall decrease in the prevalence and death rates for asthma between 1990 and 2015, according to the results of the 2015 Global Burden of Disease (GBD) Study.

Conclusive evidence that supports the use of probiotics to prevent eczema and asthma in high-risk infants is lacking.

Top news of the day from across the healthcare landscape.

A study published in Pediatrics found no conclusive evidence to support the use of probiotics to prevent eczema and asthma in high-risk infants.

Some patients with asthma have symptoms uncontrolled by inhaled corticosteroids and long-acting bronchodilators.

Patients with chronic obstructive pulmonary disease often have difficulty adhering to medications, which can lead to hospitalization.

Offspring of pollutant-exposed ancestors also showed elevated levels of interleukin proteins that are involved in regulating the immune system, which are a marker of asthma risk.

An asthma drug may potentially be useful in treating type 2 diabetes, according to a recently-published study.

Amlexanox may alter genes that improve blood glucose control in patients with type 2 diabetes.

Modifying blood stem cells could turn off the immune response to an allergen.

Researchers at the University of Bristol in the United Kingdom have published a study in European Respiratory Journal that analyzed sugar intake during pregnancy and the relationship to allergies and asthma in children.

Increased global temperatures may lead to high levels of fungus in the air.

Imatinib (Gleevec) observed to open airways in patients with severe asthma.

Top news of the day from across the health care landscape.

New method identifies disease risk for asthma across genetic markers.

Benralizumab led to a significant reduction in the use of oral corticosteroids for patients with severe, uncontrolled eosinophilic asthma.

Imatinib found to reduce measures of airway inflammation in severe asthma.

Cancer drug shows promise improving asthma symptoms.

An early-phase study suggests that a targeted cancer drug, imatinib (Gleevec, Novartis), may help treat patients with severe asthma.

Most children with asthma have symptoms that are controlled through low to moderate doses of inhaled corticosteroids.

Budesonide/formoterol resulted in a statistically significantly greater improvement than budesonide alone in asthma patients age 12 and under.

Inhaled combination of budesonide and formoterol shows promise treating asthma in children aged 6 to 12.